UNSPSC 51101678: Ponazuril

This classification denotes an antiprotozoal agent with the molecular formula C18H14F3N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JPW84AS66U, chemically known as 1-methyl-3-(4-(p-((trifluoromethyl)sulfonyl)phenoxy)-m-tolyl)-s-triazine-2,4,6(1h,3h,5h)-trione. but generally known as ponazuril, which bears US NIH Compound Identifier 3050408. The term PONAZURIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42).

Most nations schedule ponazuril under HS 29336980 and SITC 51576. As of Q4 2014, PONAZURIL remains the US FDA Preferred Term for this commodity. Ponazuril bears US NLM identifiers UMLS ID C0961649 and NCI Concept Code C72600. SMILES: CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F.

UNSPSC 51101678 Ponazuril (Commodity) does not reflect the actual pharmaceutical and medical supply procurement activity appearing in recent state and local opportunities tagged under this code. The two most recent solicitations involve naloxone, drug deactivation systems, doxycycline hyclate, and ciprofloxacin hydrochloride — none of which are ponazuril or closely related veterinary antiprotozoal agents. State and local buyers using this code designation appear to be acquiring emergency response pharmaceuticals, infectious-disease treatments, and harm-reduction supplies through competitive bidding and cooperative purchasing consortia rather than the single-product category the code nominally describes.

Issuing bodies include county health departments and state public health agencies. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical piggyback contract through the MMCAP Infuse cooperative purchasing vehicle to Chartwell Rx LLC in August 2026; Seminole County, Florida issued an IFB in June 2026 for naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term plus one-year renewal option. The code shows recent activity in Illinois and Florida, though the tag-to-scope mismatch suggests either broad category designation or data-entry inconsistency in the underlying procurement records. Buyers in this segment typically use cooperative purchasing vehicles, require E-Verify compliance and drug-free workplace certification, and expect vendors to absorb shipping and delivery costs. The actual procurement demand under this code is not well-aligned with the commodity name; firms should verify the specific pharmaceutical or medical product categories their target buyers are actually purchasing before positioning.